Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sevrin

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptorsG Griebel, G Perrault, J Simiand, et al.
Minerva Pediatrica|May 20, 2014
Association between mode of delivery and neonatal deaths and complications in term pregnancy: a cohort study in BrazilL C Machado Júnior, C E Sevrin, E Oliveira, et al.
Cancer Medicine|November 29, 2024
Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma: A Report from the French Society of Pediatric Oncology Malignant Mesenchymal Tumor CommitteeFrançois Sevrin, Emilie Bogart, Daniel Orbach, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2002
SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repairBadia Ferzaz, Emmanuel Brault, Genevieve Bourliaud, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 7, 2003
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profileYves Claustre, Danielle De Peretti, Philippe Brun, et al.
Pediatric Blood & Cancer|August 14, 2023
Phase II study of <sup>131</sup> I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOPFrançois Sevrin, Hélène Kolesnikov-Gauthier, Olivier Cougnenc, et al.
Cadernos De Saude Publica|January 31, 2009
[Association between mode of delivery and maternal complications in a public hospital in Greater Metropolitan São Paulo, Brazil]Luís Carlos Machado Junior, Christian Eric Sevrin, Emerson de Oliveira, et al.
Signal Transduction and Targeted Therapy|April 21, 2026
Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemiaFanny Gonzales, Pauline Peyrouze, Djohana Laurent, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychoticRonan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptorsG Griebel, G Perrault, J Simiand, et al.
Minerva Pediatrica|May 20, 2014
Association between mode of delivery and neonatal deaths and complications in term pregnancy: a cohort study in BrazilL C Machado Júnior, C E Sevrin, E Oliveira, et al.
Cancer Medicine|November 29, 2024
Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma: A Report from the French Society of Pediatric Oncology Malignant Mesenchymal Tumor CommitteeFrançois Sevrin, Emilie Bogart, Daniel Orbach, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2002
SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repairBadia Ferzaz, Emmanuel Brault, Genevieve Bourliaud, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 7, 2003
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profileYves Claustre, Danielle De Peretti, Philippe Brun, et al.
Pediatric Blood & Cancer|August 14, 2023
Phase II study of <sup>131</sup> I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOPFrançois Sevrin, Hélène Kolesnikov-Gauthier, Olivier Cougnenc, et al.
Cadernos De Saude Publica|January 31, 2009
[Association between mode of delivery and maternal complications in a public hospital in Greater Metropolitan São Paulo, Brazil]Luís Carlos Machado Junior, Christian Eric Sevrin, Emerson de Oliveira, et al.
Signal Transduction and Targeted Therapy|April 21, 2026
Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemiaFanny Gonzales, Pauline Peyrouze, Djohana Laurent, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychoticRonan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, et al.
Pageof 12